SAN JOSE, Calif., May 7, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, today announced that the Harmony™ Prenatal Test will be available in the United States and Canada through Laboratory Corporation of America® Holdings (LabCorp®) and Integrated Genetics, a member of LabCorp's Specialty Testing Group. Harmony represents an innovative non-invasive test for detection of common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood. The Harmony Prenatal Test is currently available in selected locations and will be broadly available next month.
"Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians," said Ken Song, MD, chief executive officer at Ariosa Diagnostics. "With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."
The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 (associated with Down syndrome), will be offered through LabCorp and will be available at its 1,000+ patient service centers. The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
"We are pleased to be able to offer this novel, non-invasive prenatal test," indicated Mark Brecher, MD, LabCorp's chief medical o
|SOURCE Ariosa Diagnostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved